AIMS: This study, conducted in a 'field-practice' scenario, investigates the effectiveness and safety of everolimus in the second-line treatment of metastatic renal cell carcinoma (mRCC) patients. PATIENTS & METHODS: mRCC patients, who started everolimus 10 mg/day after failure of first-line VEGF receptor-targeted tyrosine kinase inhibitor, were included in this study. Study end points were treatment response, progression-free survival and tolerability. RESULTS: In total, 100 patients were assessed; the median duration of everolimus treatment was 7.1 months (95% CI: 5.7-8.5). A total of 19% of patients experienced a partial response and 62% of patients reached a stable disease. Median progression-free survival was 8 months (95% CI: 6.7-9.3). A total of 75% of patients experienced adverse events; no grade 4 adverse events were reported. CONCLUSION: These findings, obtained in a 'field-practice' scenario, support the use of everolimus for mRCC patients who failed one VEGF receptor-targeted tyrosine kinase inhibitor.
AIMS: This study, conducted in a 'field-practice' scenario, investigates the effectiveness and safety of everolimus in the second-line treatment of metastatic renal cell carcinoma (mRCC) patients. PATIENTS & METHODS: mRCC patients, who started everolimus 10 mg/day after failure of first-line VEGF receptor-targeted tyrosine kinase inhibitor, were included in this study. Study end points were treatment response, progression-free survival and tolerability. RESULTS: In total, 100 patients were assessed; the median duration of everolimus treatment was 7.1 months (95% CI: 5.7-8.5). A total of 19% of patients experienced a partial response and 62% of patients reached a stable disease. Median progression-free survival was 8 months (95% CI: 6.7-9.3). A total of 75% of patients experienced adverse events; no grade 4 adverse events were reported. CONCLUSION: These findings, obtained in a 'field-practice' scenario, support the use of everolimus for mRCC patients who failed one VEGF receptor-targeted tyrosine kinase inhibitor.
Authors: Carmine D'Aniello; Maria G Vitale; Azzurra Farnesi; Lorenzo Calvetti; Maria M Laterza; Carla Cavaliere; Chiara Della Pepa; Vincenza Conteduca; Anna Crispo; Ferdinando De Vita; Francesco Grillone; Enrico Ricevuto; Michele De Tursi; Rocco De Vivo; Marilena Di Napoli; Sabrina C Cecere; Gelsomina Iovane; Alfonso Amore; Raffaele Piscitelli; Giuseppe Quarto; Salvatore Pisconti; Gennaro Ciliberto; Piera Maiolino; Paolo Muto; Sisto Perdonà; Massimiliano Berretta; Emanuele Naglieri; Luca Galli; Giacomo Cartenì; Ugo De Giorgi; Sandro Pignata; Gaetano Facchini; Sabrina Rossetti Journal: Front Pharmacol Date: 2016-09-28 Impact factor: 5.810
Authors: Sabrina Rossetti; Carmine D'Aniello; Gelsomina Iovane; Sarah Scagliarini; Maria M Laterza; Fernando De Vita; Clementina Savastano; Giacomo Cartenì; Maria A Porricelli; Massimiliano Berretta; Salvatore Pisconti; Gaetano Facchini; Carla Cavaliere Journal: Front Pharmacol Date: 2017-07-20 Impact factor: 5.810